Aarkstore - Tetrahydrofolate Dehydrogenase Inhibitors -Pipeline Insights, 2014

1
Tetrahydrofolate Dehydrogenase Inhibitors
-Pipeline Insights, 2014
Category Pharmaceuticals Healthcare

• Browse Complete Report -
• http//www.aarkstore.com/pharmaceuticals-healthcar
  e/76034/tetrahydrofolate-dehydrogenase-inhibitors-
  pipeline-insights-2014

2
Summary

• DelveInsights,Tetrahydrofolate Dehydrogenase
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA). A
  key objective of the report is to establish the
  understanding for all the pipeline drugs that
  fall under Tetrahydrofolate Dehydrogenase
  Inhibitors. This report provides information on
  the therapeutic development based on the
  Tetrahydrofolate Dehydrogenase Inhibitors dealing
  with mechanism of action, comparative analysis at
  various stages covering Filed, Phase III, Phase
  II, Phase I, IND filed, Preclinical, Discovery
  and unknown stages, therapeutics assessment by
  monotherapy and combination products and molecule
  type drug information. The report also covers the
  companies information involved in the therapeutic
  development of the products. It also has
  highlighted the discontinued and dormant products.

3
Summary

• Data Sources
• The report is built using data and information
  sourced from proprietary databases, primary and
  secondary research and in-house analysis by
  DelveInsight team of industry experts.Secondary
  sources information and data has been collected
  from various printable and non-printable sources
  like search engines, News websites, Government
  Websites, Trade Journals, White papers,
  Magazines, Trade associations, Books, Industry
  Portals, Industry Associations and access to
  available databases.Please note this report
  requires certain updates. We have all the
  information available but require 3 business days
  to complete the process and ensure it is as
  up-to-date as possible. Certain sections in the
  report may be removed or altered based on the
  availability and relevance of data for the
  indicated mechanism of action.

4
Summary

• Scope 
• The report provides a snapshot of the global
  therapeutic landscape of Tetrahydrofolate
  Dehydrogenase InhibitorsThe report provides
  pipeline products under drug profile section
  which includes product description, MOA,
  licensors collaborators, development partner
  and chemical informationCoverage of the
  Tetrahydrofolate Dehydrogenase Inhibitors
  pipeline on the basis of target, MOA, route of
  administration, technology involved and molecule
  typeThe report reviews key players involved in
  the therapeutics development for Tetrahydrofolate
  Dehydrogenase Inhibitors and also provide company
  profilingThe report also gives the information
  of dormant and discontinued pipeline
  projects Pipeline products coverage based on
  various stages of development ranging from
  preregistration till discovery and undisclosed
  stages Provides pipeline assessment by
  monotherapy and combination therapy products,
  stage of development and molecule type

5
Summary

• Reasons to buyComplete MOA intelligence and
  complete understanding over therapeutics
  development for Tetrahydrofolate Dehydrogenase
  InhibitorsIdentify the relationship between the
  drugs and use it for target finding, drug
  repurposing, and precision medicine.Devise
  corrective measures for pipeline projects by
  understanding Tetrahydrofolate Dehydrogenase
  Inhibitors pipeline depth and focus of Indication
  therapeutics Developing strategic initiatives to
  support your drug development activities.Optimize
  your portfolio and keep you in touch with the
  rapidly changing pharmaceutical markets, and make
  the best decisions for your business.

6
Summary

• Develop and design in licensing and out licensing
  strategies by identifying prospective partners
  with the most attractive projects to enhance and
  expand business potential and ScopeProvides
  strategically significant competitor information,
  analysis, and insights to formulate effective RD
  development strategies Modify the therapeutic
  portfolio by identifying discontinued projects
  and understanding the factors that drove them
  from pipelineGaining a Full Picture of the
  Competitive Landscape for Evidence based
  Decisions

7
Table of Content

• Tetrahydrofolate Dehydrogenase Inhibitors
  OverviewTetrahydrofolate Dehydrogenase
  Inhibitors Disease AssociatedTetrahydrofolate
  Dehydrogenase Inhibitors Pipeline
  TherapeuticsTetrahydrofolate Dehydrogenase
  Inhibitors Therapeutics under Development by
  Companies Tetrahydrofolate Dehydrogenase
  Inhibitors Late Stage Products (Filed and Phase
  III)Comparative Analysis Tetrahydrofolate
  Dehydrogenase Inhibitors Mid Clinical Stage
  Products (Phase II)Comparative
  Analysis Tetrahydrofolate Dehydrogenase
  Inhibitors Early Clinical Stage Products (Phase I
  and IND Filed)Comparative Analysis Tetrahydrofol
  ate Dehydrogenase Inhibitors Discovery and
  Pre-Clinical Stage Products Comparative
  Analysis Drug Candidate Profiles

8
Table of Content

• Tetrahydrofolate Dehydrogenase Inhibitors
  Therapeutics Assessment Assessment by
  Monotherapy Products Assessment by Combination
  Products Assessment by Route of
  Administration Assessment by Molecule
  Type Tetrahydrofolate Dehydrogenase Inhibitors
  Discontinued Products Tetrahydrofolate
  Dehydrogenase Inhibitors Dormant
  ProductsCompanies Involved in Therapeutics
  Development for Tetrahydrofolate Dehydrogenase
  Inhibitors Appendix Methodology Contact
  Us Disclaimer

9
List of Tables

• Number of Products under Development for
  Tetrahydrofolate Dehydrogenase Inhibitors by
  Therapy Area, 2014Number of Products under
  Development for Tetrahydrofolate Dehydrogenase
  Inhibitors, 2014Number of Products under
  Development by Companies Comparative Analysis by
  Late Clinical Stage Products (Filed and Phase
  III), 2014Comparative Analysis Mid Clinical
  Stage Products (Phase II), 2014Comparative
  Analysis Early Clinical Stage Products (Phase I
  and IND Filed), 2014Comparative Analysis
  Discovery and Pre-Clinical Stage Products,
  2014Drug Candidates Profiles

10
List of Tables

• Tetrahydrofolate Dehydrogenase Inhibitors
  Assessment by Monotherapy Products Tetrahydrofola
  te Dehydrogenase Inhibitors Assessment by
  Combination Products Tetrahydrofolate
  Dehydrogenase Inhibitors Assessment by Route of
  Administration Tetrahydrofolate Dehydrogenase
  Inhibitors Assessment by Stage and Route of
  Administration Tetrahydrofolate Dehydrogenase
  Inhibitors Assessment by Molecule
  Type Tetrahydrofolate Dehydrogenase Inhibitors
  Assessment by Stage and Molecule
  Type Tetrahydrofolate Dehydrogenase Inhibitors
  Therapeutics Discontinued Products Tetrahydrofola
  te Dehydrogenase Inhibitors Therapeutics Dormant
  ProductsProducts under Development by Companies,
  2014

11
List of Figures

• Number of Products under Development for
  Tetrahydrofolate Dehydrogenase Inhibitors by
  Therapy Area, 2014Number of Products under
  Development for Tetrahydrofolate Dehydrogenase
  Inhibitors, 2014Late Clinical Stage Products
  (Filed and Phase III), 2014Mid Clinical Stage
  Products (Phase II), 2014Early Clinical Stage
  Products (Phase I and IND Filed), 2014Discovery
  and Pre-Clinical Stage Products,
  2014Tetrahydrofolate Dehydrogenase Inhibitors
  Assessment by Monotherapy Products Tetrahydrofola
  te Dehydrogenase Inhibitors Assessment by
  Combination Products Tetrahydrofolate
  Dehydrogenase Inhibitors Assessment by Route of
  Administration Tetrahydrofolate Dehydrogenase
  Inhibitors Assessment by Stage and Route of
  Administration Tetrahydrofolate Dehydrogenase
  Inhibitors Assessment by Molecule
  Type Tetrahydrofolate Dehydrogenase Inhibitors
  Assessment by Stage and Molecule Type

12
Related Reports

• The Mobile Healthcare (mHealth) Bible 2014 -
  2020
• Pregnancy Detection Kit Market in the US
  2015-2019
• Global Prenatal and Newborn Genetic Testing
  Market 2015-2019
• Global Knee Implant market 2015-2019
• Global Isosorbide Market 2015-2019
• Ascension Health - Pharmaceuticals Healthcare -
  Deals and Alliances Profile
• Accretive Health, Inc. (ACHI) - Strategic SWOT
  Analysis Review
• Jazz Pharmaceuticals plc (JAZZ) - Financial and
  Strategic SWOT Analysis Review
• Pharmstandard (PHST) - Financial and Strategic
  SWOT Analysis Review
• GLG Life Tech Corporation (GLG) - Financial and
  Strategic SWOT Analysis Review

13

• Tetrahydrofolate Dehydrogenase Inhibitors
  -Pipeline Insights, 2014
• Published Dec. 2014 60 Pages
• DelveInsights,Tetrahydrofolate Dehydrogenase
  Inhibitors-Pipeline Insights, 2014, report
  provides comprehensive insights about pipeline
  drugs across this mechanism of action (MOA).
  
  Price

Format Price
PDF 1250
Site Licence 2500
Enterprise Wide Licence 4000
14
Contact Us
Office Office No. - 809, 8th Floor,B-Wing,
Mahaavir Icon, Plot No.- 89 90,
Sector-15,CBD-Belapur, Navi Mumbai
400614, Maharashtra, India. Telefax No 91 22
4127 6660 24/7 Online Support 91
9987295242 General Inquiries 91 - 22 2756 4953

• You Can Visit http//www.aarkstore.com
• OR Mail us at contact_at_aarkstore.com
• Blog
• http//www.aarkstore.com/blog/
• Conference
• http//conference.aarkstore.com/
• News
• http//www.aarkstore.com/news